Develops prophylactic vaccines for infectious diseases.
Dec 2025Revenue €175M/yrExpenses €257M/yr
No trendCash runway ≈ 1.9 years from Dec 2025
Figures by year
When will Valneva be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was €175M and expenses €257M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | €175M | €257M | −€82.1M |
| Dec 2024 | €170M | €156M | €13.3M |
| Dec 2023 | €154M | €236M | −€82.1M |
| Dec 2022 | €361M | €475M | −€113M |
| Dec 2021 | €348M | €409M | −€61.4M |
| Dec 2020 | €110M | €165M | −€55.1M |
| Dec 2019 | €126M | €127M | −€811K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.